Aurigene to Present its Programs on Covalent, Selective CDK7 Inhibitors, Novel Peptide Antagonists of CD47-SIRPα Interaction and Inhibitors of MALT-1 Signalling at the AACR 2017

India - English

• USA - English

1. Proprietary novel, first-in-class, peptide antagonists of CD47-SIRPα interaction program which is currently in late lead optimization stage,
2. Preclinical stage covalent, highly selective CDK7 inhibitors program and
3. Selective, covalent inhibitors of MALT-1 signalling  program.

     (Logo: http://photos.prnewswire.com/prnh/20130418/608115 )

Additional information on the presentations can be found below and abstracts can be accessed at http://www.aacr.org.  

Poster Presentations 

Peptide antagonists targeting CD47- SIRPα 

- Title: Targeting CD47- SIRPα interaction by novel peptide-based antagonists 

- Session Category: Immunology

- Session Title: Tumor Microenvironment and Checkpoints

- Session Date and Time: Monday Apr 3, 2017 8:00 AM - 12:00 PM 

- Location: Convention Center, Halls A-C, Poster Section 27

- Poster Board Number: 28

- Permanent Abstract Number: 1650

Covalent, selective, CDK7 inhibitors 

- Title: Identification of a novel preclinical candidate for CDK7 inhibition  

- Session Title: Late-Breaking Research: Mol Cell Biology 4

- Session Date and Time: Wednesday Apr 5, 2017 8:00 AM - 12:00 PM  

- Session Location: Poster Section 36

- Poster Board Number: 3

- Permanent Abstract Number: LB-317

Covalent, MALT-1 Inhibitors 

- Title: Potent small molecule compounds that selectively inhibit proliferation of ABC-DLBCL cell lines 

- Session Category: Experimental and Molecular Therapeutics

- Session Title: Novel Chemotherapies

- Session Date and Time: Wednesday Apr 5, 2017 8:00- 12:00 PM 

- Location: Convention Center, Halls A-C, Poster Section 4

- Poster Board Number: 10

- Permanent Abstract Number: 5108

About Aurigene 

Aurigene is a specialized biotechnology company, engaged in discovery and early clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene is focused on oral check-point inhibitors, precision-oncology and the Th-17 pathway. Aurigene's oral PD-L1/ VISTA antagonist program is currently in Phase 1 clinical development with its partner. Aurigene has partnered with several large- and mid-pharma companies in the United States and Europe and has delivered over 15 compounds which are in clinical development.

For more information, please visit Aurigene's website at: http://aurigene.com/.

Media Contact:
Rajshree KT
Director Strategic Alliances
+91-40-4465-7777